Inovio Pharmaceuticals, Inc.

INO04 Dec 2024
Healthcare
$4.38
-0.03 (-3.45%)
Lowest Today
$4.15
Highest Today
$4.61
Today’s Open
$4.38
Prev. Close
$4.35
52 Week High
$14.75
52 Week Low
$3.85
To Invest in Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc.

Healthcare
INO04 Dec 2024
-0.03 (-3.45%)
1M
3M
6M
1Y
5Y
Low
$4.15
Day’s Range
High
$4.61
4.15
52 Week Low
$3.85
52-Week Range
52 Week High
$14.75
3.85
1 Day
-
1 Week
-0.11%
1 month return
-24.09%
3 month return
-36.27%
6 month return
-58.63%
1 Year return
-13.78%
3 Years return
-94.27%
5 Years return
-85.89%
10 Years return
-
Institutional Holdings
Deep Track Capital, LP
6.91
Vanguard Group Inc
6.89
BlackRock Inc
6.54
Vanguard Total Stock Mkt Idx Inv
3.14
iShares Russell 2000 ETF
2.81
Geode Capital Management, LLC
2.38
State Street Corp
1.88

Market Status

Fundamentals
Market Cap
113.54 mln
PB Ratio
1.53
PE Ratio
0
Enterprise Value
40.39 mln
Total Assets
172.94 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Organisation
Inovio Pharmaceuticals, Inc.
Employees
127
Industry
Biotechnology
CEO
Dr. Jacqueline E. Shea Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities